Literature DB >> 30955360

Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.

David A Morrow1,2, Eric J Velazquez3, Adam D DeVore4, Akshay S Desai2, Carol I Duffy5, Andrew P Ambrosy6,7, Yared Gurmu1, Kevin McCague5, Ricardo Rocha5, Eugene Braunwald1,2.   

Abstract

Entities:  

Keywords:  enalapril; heart failure; hospitalization; valsartan

Mesh：

Substances：

Year:  2019        PMID： 30955360     DOI： 10.1161/CIRCULATIONAHA.118.039331

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  40 in total

Review 1.  HDL therapy today: from atherosclerosis, to stent compatibility to heart failure.

Authors:  C R Sirtori; M Ruscica; L Calabresi; G Chiesa; R Giovannoni; J J Badimon
Journal:  Ann Med       Date:  2019 Nov - Dec       Impact factor: 4.709

2.  Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.

Authors:  Muthiah Vaduganathan; Brian L Claggett; Akshay S Desai; Stefan D Anker; Sergio V Perrone; Stefan Janssens; Davor Milicic; Juan L Arango; Milton Packer; Victor C Shi; Martin P Lefkowitz; John J V McMurray; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2019-11-11       Impact factor: 24.094

3.  Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis.

Authors:  Domenico Acanfora; Pietro Scicchitano; Chiara Acanfora; Roberto Maestri; Fernando Goglia; Raffaele Antonelli Incalzi; Alessandro Santo Bortone; Marco Matteo Ciccone; Massimo Uguccioni; Gerardo Casucci
Journal:  Clin Drug Investig       Date:  2020-05       Impact factor: 2.859

4.  Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.

Authors:  David D Berg; Eugene Braunwald; Adam D DeVore; Anuradha Lala; Sean P Pinney; Carol I Duffy; Yared Gurmu; Eric J Velazquez; David A Morrow
Journal:  JACC Heart Fail       Date:  2020-08-12       Impact factor: 12.035

5.  Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.

Authors:  Adam D DeVore; Eugene Braunwald; David A Morrow; Carol I Duffy; Andrew P Ambrosy; Hrishikesh Chakraborty; Kevin McCague; Ricardo Rocha; Eric J Velazquez
Journal:  JAMA Cardiol       Date:  2020-02-01       Impact factor: 14.676

Review 6.  Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment.

Authors:  Koichi Yamamoto; Hiromi Rakugi
Journal:  Hypertens Res       Date:  2021-07-21       Impact factor: 3.872

7.  Improvement in quality of life with sacubitril/ /valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry.

Authors:  José Manuel Rubio Campal; Hugo Del Castillo; Belén Arroyo Rivera; Carmen de Juan Bitriá; Mikel Taibo Urquia; Pepa Sánchez Borque; Ángel Miracle Blanco; Loreto Bravo Calero; David Martí Sánchez; José Tuñón Fernández
Journal:  Cardiol J       Date:  2021-02-26       Impact factor: 2.737

8.  Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.

Authors:  David D Berg; Marc D Samsky; Eric J Velazquez; Carol I Duffy; Yared Gurmu; Eugene Braunwald; David A Morrow; Adam D DeVore
Journal:  Circ Heart Fail       Date:  2021-02-03       Impact factor: 8.790

9.  Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.

Authors:  Marat Fudim; Sabina Sayeed; Haolin Xu; Roland A Matsouaka; Paul A Heidenreich; Eric J Velazquez; Clyde W Yancy; Gregg C Fonarow; Adrian F Hernandez; Adam D DeVore
Journal:  Circ Heart Fail       Date:  2020-04-06       Impact factor: 8.790

10.  2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.

Authors:  Paul A Heidenreich; Gregg C Fonarow; Khadijah Breathett; Corrine Y Jurgens; Barbara A Pisani; Bunny J Pozehl; John A Spertus; Kenneth G Taylor; Jennifer T Thibodeau; Clyde W Yancy; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2020-11-02       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.